206 related articles for article (PubMed ID: 23705623)
1. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system.
Schleidgen S; Marckmann G
BMC Med Ethics; 2013 May; 14():20. PubMed ID: 23705623
[TBL] [Abstract][Full Text] [Related]
2. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine.
McGowan ML; Settersten RA; Juengst ET; Fishman JR
Urol Oncol; 2014 Feb; 32(2):187-92. PubMed ID: 24445286
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. My Data, My Choice? - German Patient Organizations' Attitudes towards Big Data-Driven Approaches in Personalized Medicine. An Empirical-Ethical Study.
Rauter CM; Wöhlke S; Schicktanz S
J Med Syst; 2021 Feb; 45(4):43. PubMed ID: 33616768
[TBL] [Abstract][Full Text] [Related]
5. Individual health services.
Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on Precision Medicine in a Tribally Managed Primary Care Setting.
Beans JA; Woodbury RB; Wark KA; Hiratsuka VY; Spicer P
AJOB Empir Bioeth; 2020; 11(4):246-256. PubMed ID: 32940567
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine and economic evaluation in oncology: all theory and no practice?
Garattini L; Curto A; Freemantle N
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
[TBL] [Abstract][Full Text] [Related]
9. Translating genomics in cancer care.
Bombard Y; Bach PB; Offit K
J Natl Compr Canc Netw; 2013 Nov; 11(11):1343-53. PubMed ID: 24225968
[TBL] [Abstract][Full Text] [Related]
10. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
[TBL] [Abstract][Full Text] [Related]
11. Envisioning the Future of Personalized Medicine: Role and Realities of Digital Twins.
Vallée A
J Med Internet Res; 2024 May; 26():e50204. PubMed ID: 38739913
[TBL] [Abstract][Full Text] [Related]
12. Patient and interest organizations' views on personalized medicine: a qualitative study.
Budin-Ljøsne I; Harris JR
BMC Med Ethics; 2016 May; 17(1):28. PubMed ID: 27178188
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in psychiatry: ethical challenges and opportunities.
Evers K
Dialogues Clin Neurosci; 2009; 11(4):427-34. PubMed ID: 20135900
[TBL] [Abstract][Full Text] [Related]
14. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
Lange J; Gönner C; Vollmann J; Rauprich O
Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
[TBL] [Abstract][Full Text] [Related]
15. [Ethical and theoretical medical comments on the desire and reality of individualised medicine].
Paul NW; Mitzkat A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1473-9. PubMed ID: 24170076
[TBL] [Abstract][Full Text] [Related]
16. Organizations Towards "Big Data"-Driven Approaches in Personalized Medicine? An Empirical-Ethical Study in Health-Related IT.
Rauter CM; Wöhlke S; Schicktanz S
Stud Health Technol Inform; 2019; 258():199-200. PubMed ID: 30942745
[TBL] [Abstract][Full Text] [Related]
17. Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.
Bertier G; Carrot-Zhang J; Ragoussis V; Joly Y
Genome Med; 2016 Oct; 8(1):108. PubMed ID: 27776531
[TBL] [Abstract][Full Text] [Related]
18. Ask not what personalized medicine can do for you--ask what you can do for personalized medicine.
Budin-Ljøsne I; Harris JR
Public Health Genomics; 2015; 18(3):131-8. PubMed ID: 25766382
[TBL] [Abstract][Full Text] [Related]
19. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
Tsimberidou AM; Ringborg U; Schilsky RL
Am Soc Clin Oncol Educ Book; 2013; ():118-25. PubMed ID: 23714475
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
